Immunic, Inc. (IMUX) stock
IMUXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.52−0.27 (-3.47%)
Close on Nov 13, 2026Market cap $102.61MP/E –Yield 0.00%
Immunic ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Immunic's ebitda for the twelve months ending Sep 30, 2026 was -$135.11M. For fiscal 2025 it was -$103.06M. The highest annual figure on record is -$8.93M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$103.06M | – |
| FY2024 | Dec 31, 2024 | -$97.92M | – |
| FY2023 | Dec 31, 2023 | -$99.11M | – |
| FY2022 | Dec 31, 2022 | -$119.41M | – |
| FY2021 | Dec 31, 2021 | -$91.58M | – |
| FY2020 | Dec 31, 2020 | -$48.93M | – |
| FY2019 | Dec 31, 2019 | -$36.98M | – |
| FY2018 | Dec 31, 2018 | -$11.98M | – |
| FY2017 | Dec 31, 2017 | -$51.66M | – |
| FY2016 | Dec 31, 2016 | -$39.46M | – |
| FY2015 | Dec 31, 2015 | -$50.79M | – |
| FY2014 | Dec 31, 2014 | -$49.26M | – |
| FY2013 | Dec 31, 2013 | -$30.60M | – |
| FY2012 | Dec 31, 2012 | -$8.93M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$43.33M | – |
| Q2 FY2026 | Jun 30, 2026 | -$35.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$33.20M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$25.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.78M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.68M | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.78M | – |
| Q1 FY2024 | Mar 31, 2024 | -$23.86M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$23.54M | – |
| Q2 FY2023 | Jun 30, 2023 | -$25.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.22M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$20.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.41M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.16M | – |
| Q1 FY2021 | Mar 31, 2021 | -$32.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$14.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.50M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.17M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.17M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.98M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.23M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.60M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$14.27M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.56M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.42M | – |
| Q2 FY2017 | Jun 30, 2017 | -$12.32M | – |
| Q1 FY2017 | Mar 31, 2017 | -$12.35M | – |
| Q4 FY2016 | Dec 31, 2016 | -$11.42M | – |
See a number that looks wrong?